Teva-Erlotinib 25 mg (Erlotinib (Erlotinib Hydrochloride) TABLET) 25 MG

Teva-Erlotinib 25 mg tablets are a targeted therapy option for certain types of cancer. This oral medication is designed to inhibit specific proteins involved in cancer cell growth, offering a precise approach to treatment.

Strength

25 MG

Pack Size

Manufacturer / TM Owner

TEVA CANADA LIMITED

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Teva-Erlotinib 25 mg tablets are primarily used in the treatment of non-small cell lung cancer and pancreatic cancer. Erlotinib, the active ingredient, works by targeting the epidermal growth factor receptor (EGFR), which plays a role in cancer cell proliferation. This medication is often considered when other treatments have not been effective or when the cancer has specific genetic markers.

Side Effects

Common effects of Teva-Erlotinib 25 mg tablets may include skin rash, diarrhea, and fatigue. Some individuals might also experience appetite loss, nausea, or dry skin. These effects can vary in intensity and duration among users.

Precautions & Warnings

Teva-Erlotinib 25 mg tablets should be handled with care, especially for individuals with pre-existing liver or kidney conditions. It is important to follow the advice of a healthcare provider regarding the use of this medication. Regular monitoring may be necessary to manage potential side effects.

Avoid Interactions

Teva-Erlotinib 25 mg tablets may interact with certain medications, including those that are metabolized by the liver's cytochrome P450 system. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Additionally, grapefruit and grapefruit juice should be avoided as they can affect the metabolism of erlotinib.

Frequently Asked Questions

Teva-Erlotinib 25 mg tablets are used to treat certain types of cancer, including non-small cell lung cancer and pancreatic cancer, by targeting specific proteins involved in cancer cell growth.

Teva-Erlotinib 25 mg tablets are taken orally, typically once daily. The exact dosage and administration should be determined by a healthcare provider.

Common side effects may include skin rash, diarrhea, fatigue, appetite loss, nausea, and dry skin. These effects can vary among individuals.

Teva-Erlotinib 25 mg may interact with certain medications, so it is important to consult a healthcare provider before combining it with other treatments.

Teva-Erlotinib 25 mg may not be suitable for individuals with certain medical conditions, such as liver or kidney issues. A healthcare provider can determine if this medication is appropriate.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.